Higher-dose portions of multiple-sclerosis studies with Laquinimod drug terminated

Stuart SchlossmanMS Drug Therapies, MS Research Study and Reports

Trucks cross in front of the Teva Pharmaceutical Logistic Center in the town of Shoam, Israel.

By 

Teva Pharmaceutical Industries Ltd. and Active Biotech AB said Monday they were ending the higher-dose portions of two multiple-sclerosis studies with the drug Laquinimod after eight patients suffered nonfatal cardiovascular events.
The companies said the incidents occurred in the higher-dose components of a phase 3 and a phase 2 clinical trial. The lower-dose and placebo components of the tests will continue.
Phase 3 clinical trials are typically the last phase before a drug gets approval from the U.S. Food and Drug Administration.
Laquinimod is a once-daily oral drug being developed for treating multiple sclerosis and Huntington disease.

Continue reading

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News 
helps to provide educational information for persons affected by MS
Keep current with Multiple Sclerosis news and information 
by opting-in to our website: click here – thank you
.===================================
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews